Boehringer Ingelheim GMBH reported 56.1% currency-adjusted growth in its diabetes business in 2016, and from 2017 the early lead in the use of diabetes medication for cardiovascular indications that it and partner Eli Lilly & Co. have established looks likely to help drive continued expansion.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?